Adagene Inc.

Adagene Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel antibody-based cancer immunotherapies. Incorporated in 2011 under the laws of the Cayman Islands, the company leverages computational biology and artificial intelligence to design innovative antibodies. Its corporate headquarters is located in Suzhou, Jiangsu Province, China.

The company's core technology is its proprietary AI-Powered Dynamic Precision Library (DPL) platform, which encompasses NEObody, SAFEbody, and POWERbody technologies. This platform enables the generation of therapeutic antibody candidates with unique functional epitopes. Adagene's pipeline includes lead product candidates such as ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, currently in clinical development for metastatic microsatellite-stable colorectal cancer. Other clinical-stage assets include ADG116, another anti-CTLA-4 antibody, and ADG106, an anti-CD137 agonist antibody, both targeting advanced solid tumors.

In recent news, Adagene received FDA Fast Track Designation in December 2025 for muzastotug (ADG126) in combination with pembrolizumab for adult patients with MSS metastatic colorectal cancer. The company has also established clinical collaborations, including one with Incyte to evaluate muzastotug in combination with Incyte's TGFβR2xPD-1 bispecific antibody for MSS CRC, with a Phase 1 study anticipated to commence in 2026. Furthermore, in July 2025, Sanofi made a strategic investment of up to $25 million in Adagene and exercised an option for a third SAFEbody discovery program, underscoring the potential of Adagene's platform and its lead programs. Dr. Peter Luo serves as the Co-founder, CEO, and Chairman of Adagene.